Legal & General Group PLC Neurocrine Biosciences Inc Transaction History

Legal & General Group PLC

  • $470 Billion
  • Q3 2024

A detailed history of Legal & General Group PLC transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Legal & General Group PLC holds 529,260 shares of NBIX stock, worth $66.4 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
529,260
Previous 574,162 7.82%
Holding current value
$66.4 Million
Previous $79 Million 22.91%
% of portfolio
0.01%
Previous 0.02%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
SELL
$114.58 - $153.15 $5.14 Million - $6.88 Million
-44,902 Reduced 7.82%
529,260 $60.9 Million
Q2 2024

Aug 14, 2024
BUY
$130.86 - $143.19 $4.46 Million - $4.88 Million
34,056 Added 6.31%
574,162 $79 Million
Q1 2024

May 14, 2024
SELL
$130.4 - $143.74 $4.8 Million - $5.29 Million
-36,782 Reduced 6.38%
540,106 $74.5 Million
Q4 2023

Feb 15, 2024
BUY
$106.07 - $132.76 $13.7 Million - $17.1 Million
128,740 Added 28.73%
576,888 $76 Million
Q3 2023

Nov 14, 2023
SELL
$94.02 - $117.1 $901,087 - $1.12 Million
-9,584 Reduced 2.09%
448,148 $50.4 Million
Q2 2023

Aug 14, 2023
SELL
$89.53 - $104.87 $3.24 Million - $3.79 Million
-36,186 Reduced 7.33%
457,732 $43.2 Million
Q1 2023

May 15, 2023
BUY
$94.11 - $123.02 $253,720 - $331,661
2,696 Added 0.55%
493,918 $50 Million
Q4 2022

Feb 14, 2023
SELL
$106.72 - $127.06 $620,683 - $738,980
-5,816 Reduced 1.17%
491,222 $58.7 Million
Q3 2022

Nov 14, 2022
SELL
$92.03 - $107.81 $890,114 - $1.04 Million
-9,672 Reduced 1.91%
497,038 $52.8 Million
Q2 2022

Aug 22, 2022
BUY
$75.79 - $100.07 $2.52 Million - $3.33 Million
33,279 Added 7.03%
506,710 $49.4 Million
Q1 2022

May 16, 2022
BUY
$72.45 - $94.81 $1.9 Million - $2.49 Million
26,254 Added 5.87%
473,431 $44.4 Million
Q4 2021

Feb 14, 2022
SELL
$79.65 - $106.22 $234,489 - $312,711
-2,944 Reduced 0.65%
447,177 $38.1 Million
Q3 2021

Nov 15, 2021
BUY
$86.18 - $99.03 $140,042 - $160,923
1,625 Added 0.36%
450,121 $43.2 Million
Q2 2021

Aug 12, 2021
BUY
$89.43 - $102.27 $3.84 Million - $4.39 Million
42,915 Added 10.58%
448,496 $43.6 Million
Q1 2021

May 17, 2021
BUY
$87.57 - $119.4 $5.86 Million - $7.99 Million
66,890 Added 19.75%
405,581 $39.4 Million
Q4 2020

Feb 12, 2021
SELL
$86.91 - $108.33 $2.56 Million - $3.19 Million
-29,488 Reduced 8.01%
338,691 $32.5 Million
Q3 2020

Nov 13, 2020
SELL
$96.16 - $135.15 $894,864 - $1.26 Million
-9,306 Reduced 2.47%
368,179 $35.4 Million
Q2 2020

Aug 14, 2020
BUY
$85.09 - $130.36 $8.08 Million - $12.4 Million
94,980 Added 33.62%
377,485 $46.1 Million
Q1 2020

May 14, 2020
BUY
$75.11 - $113.76 $1.59 Million - $2.41 Million
21,196 Added 8.11%
282,505 $24.5 Million
Q4 2019

Feb 13, 2020
BUY
$86.8 - $118.57 $17.1 Million - $23.4 Million
197,544 Added 309.8%
261,309 $28.1 Million
Q3 2019

Nov 13, 2019
BUY
$83.82 - $101.5 $961,163 - $1.16 Million
11,467 Added 21.93%
63,765 $5.75 Million
Q2 2019

Aug 14, 2019
BUY
$72.24 - $91.27 $51,868 - $65,531
718 Added 1.39%
52,298 $4.42 Million
Q1 2019

May 15, 2019
SELL
$69.31 - $91.53 $622,888 - $822,580
-8,987 Reduced 14.84%
51,580 $4.54 Million
Q4 2018

Feb 15, 2019
SELL
$68.32 - $124.36 $314,135 - $571,807
-4,598 Reduced 7.06%
60,567 $4.33 Million
Q3 2018

Nov 20, 2018
BUY
$98.88 - $125.85 $2.51 Million - $3.19 Million
25,365 Added 63.73%
65,165 $8.01 Million
Q2 2018

Aug 10, 2018
SELL
$75.3 - $105.99 $377,328 - $531,115
-5,011 Reduced 11.18%
39,800 $3.91 Million
Q1 2018

May 17, 2018
SELL
$75.88 - $92.43 $42,568 - $51,853
-561 Reduced 1.24%
44,811 $3.72 Million
Q4 2017

Feb 13, 2018
BUY
$58.53 - $77.59 $2.66 Million - $3.52 Million
45,372
45,372 $3.52 Million

Others Institutions Holding NBIX

# of Institutions
629
Shares Held
94.2M
Call Options Held
692K
Put Options Held
406K
View Full List

About NEUROCRINE BIOSCIENCES INC

NBIX Quotes by TradingView
  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $12B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Legal & General Group PLC Portfolio

Follow Legal & General Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email